Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Stacy L. Moulder"'
Autor:
Gloria V. Echeverria, Shirong Cai, Yizheng Tu, Jiansu Shao, Emily Powell, Abena B. Redwood, Yan Jiang, Aaron McCoy, Amanda L. Rinkenbaugh, Rosanna Lau, Alexander J. Trevarton, Chunxiao Fu, Rebekah Gould, Elizabeth E. Ravenberg, Lei Huo, Rosalind Candelaria, Lumarie Santiago, Beatriz E. Adrada, Deanna L. Lane, Gaiane M. Rauch, Wei T. Yang, Jason B. White, Jeffrey T. Chang, Stacy L. Moulder, W. Fraser Symmans, Susan G. Hilsenbeck, Helen Piwnica-Worms
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patient-derived xenograft (PDX) models of breast cancer are an effective discovery platform and tool for preclinical pharmacologic testing and biomarker identification. We established orthotopic PDX models of triple negative breast cancer (T
Externí odkaz:
https://doaj.org/article/1aeaec90b47b427c8b0d10b0dad9ddf6
Autor:
Zahi I. Mitri, Nour Abuhadra, Shaun M. Goodyear, Evthokia A. Hobbs, Andy Kaempf, Alastair M. Thompson, Stacy L. Moulder
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-5 (2022)
Abstract Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity to enhance clinical management. We applied an Evolutionary Action Score to functionally characterize TP53 mutations (EAp53) in 9
Externí odkaz:
https://doaj.org/article/9f43d2c137084c2b949a03adf0c1d3b4
Autor:
Xuan Liu, Zhongqi Ge, Fei Yang, Alejandro Contreras, Sanghoon Lee, Jason B. White, Yiling Lu, Marilyne Labrie, Banu K. Arun, Stacy L. Moulder, Gordon B. Mills, Helen Piwnica-Worms, Jennifer K. Litton, Jeffrey T. Chang
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract Germline mutations in BRCA1 or BRCA2 exist in ~2–7% of breast cancer patients, which has led to the approval of PARP inhibitors in the advanced setting. We have previously reported a phase II neoadjuvant trial of single agent talazoparib f
Externí odkaz:
https://doaj.org/article/c1596f6b174a47a78043a40e8d62cdcd
Autor:
Amy S. Clark, Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, Laura J. van ‘t Veer, Douglas Yee, Stacy L. Moulder, Anne M. Wallace, A. Jo Chien, Claudine Isaacs, Judy C. Boughey, Kathy S. Albain, Kathleen Kemmer, Barbara B. Haley, Hyo S. Han, Andres Forero-Torres, Anthony Elias, Julie E. Lang, Erin D. Ellis, Rachel Yung, Debu Tripathy, Rita Nanda, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Rosa I. Gallagher, Teresa Helsten, Erin Roesch, Cheryl A. Ewing, Michael Alvarado, Erin P. Crane, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Katherine Steeg, Adam Asare, Jeffrey B. Matthews, Scott Berry, Ashish Sanil, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, Richard B. Schwab, W. Fraser Symmans, Nola M. Hylton, Donald A. Berry, Laura J. Esserman, Angela M. DeMichele
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
HER2-targeted therapy improves patient’s outcome in early breast cancer. Here, the authors present the efficacy and biomarker analysis of two HER2-targeted combinations (ado-trastuzumab emtansine plus pertuzumab and paclitaxel, trastuzumab and pert
Externí odkaz:
https://doaj.org/article/e6340916dac6476fac8b24ed5afd32c1
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Vrutant V. Shah, Aundrietta D. Duncan, Shiming Jiang, Sabrina A. Stratton, Kendra L. Allton, Clinton Yam, Abhinav Jain, Patrick M. Krause, Yue Lu, Shirong Cai, Yizheng Tu, Xinhui Zhou, Xiaomei Zhang, Yan Jiang, Christopher L. Carroll, Zhijun Kang, Bin Liu, Jianjun Shen, Mihai Gagea, Sebastian M. Manu, Lei Huo, Michael Gilcrease, Reid T. Powell, Lei Guo, Clifford Stephan, Peter J. Davies, Jan Parker-Thornburg, Guillermina Lozano, Richard R. Behringer, Helen Piwnica-Worms, Jeffrey T. Chang, Stacy L. Moulder, Michelle Craig Barton
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
Human metaplastic breast cancers (MpBC) are a rare, aggressive subclass of triple-negative breast cancers. Here, the authors show over-expression of histone reader TRIM24 is sufficient to generate tumors with a molecular signature of metabolic dysfun
Externí odkaz:
https://doaj.org/article/d198e1ab2b18460f8fd9661445a6e392
Autor:
Hua Guo, Qingqing Ding, Yun Gong, Michael Z. Gilcrease, Min Zhao, Jun Zhao, Dawen Sui, Yun Wu, Hui Chen, Hui Liu, Jinxia Zhang, Erika Resetkova, Stacy L. Moulder, Wei-Lien Wang, Lei Huo
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-18 (2020)
Abstract Background In the evaluation of PD-L1 expression to select patients for anti-PD-1/PD-L1 treatment, uniform guidelines that account for different immunohistochemistry assays, different cell types and different cutoff values across tumor types
Externí odkaz:
https://doaj.org/article/29a330368cbc48e28aed14ab596d3b71
Autor:
Gloria V. Echeverria, Emily Powell, Sahil Seth, Zhongqi Ge, Alessandro Carugo, Christopher Bristow, Michael Peoples, Frederick Robinson, Huan Qiu, Jiansu Shao, Sabrina L. Jeter-Jones, Xiaomei Zhang, Vandhana Ramamoorthy, Shirong Cai, Wenhui Wu, Giulio Draetta, Stacy L. Moulder, William F. Symmans, Jeffrey T. Chang, Timothy P. Heffernan, Helen Piwnica-Worms
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-17 (2018)
It is unclear how intra-tumoral heterogeneity contributes to metastasis. Here the authors study the clonal dynamics of triple negative breast cancer metastasis using patient derived xenografts and demonstrate that primary tumor clones harbor properti
Externí odkaz:
https://doaj.org/article/d84938082d1647899042d8810ab7582c
Autor:
Filip Janku, David S. Hong, Siqing Fu, Sarina A. Piha-Paul, Aung Naing, Gerald S. Falchook, Apostolia M. Tsimberidou, Vanda M. Stepanek, Stacy L. Moulder, J. Jack Lee, Rajyalakshmi Luthra, Ralph G. Zinner, Russell R. Broaddus, Jennifer J. Wheler, Razelle Kurzrock
Publikováno v:
Cell Reports, Vol 6, Iss 2, Pp 377-387 (2014)
Despite a wealth of preclinical studies, it is unclear whether PIK3CA or phosphatase and tensin homolog (PTEN) gene aberrations are actionable in the clinical setting. Of 1,656 patients with advanced, refractory cancers tested for PIK3CA or PTEN abno
Externí odkaz:
https://doaj.org/article/121a3483acb24454b24b119984535acb